Key Takeaways
- Shares touched an annual bottom at $427.79, declining almost 6% in a single session
- Year-to-date losses exceed 20%, with a 16% decline over the trailing 12-month period
- Major institutional holders have reduced their positions in recent months
- Ongoing FDA safety concerns and recalls related to da Vinci surgical systems continue to impact investor confidence
- Wall Street remains optimistic, with 15 analysts raising earnings forecasts and several firms holding Outperform ratings
Shares of Intuitive Surgical (ISRG) tumbled to an annual low of $427.79 during Monday’s trading session, shedding approximately 6% as concerns over institutional divestment and product safety issues pressured the medical device leader.
Intuitive Surgical, Inc., ISRG
This decline pushes ISRG’s losses beyond 20% for the current year, marking a challenging period for a company that delivered impressive first-quarter 2026 performance just a few weeks earlier.
During Q1, the robotic surgery pioneer reported revenue growth of 23% to reach $2.77 billion, while earnings per share surged 38% to $2.50. These metrics exceeded Wall Street’s expectations — topping revenue projections by 6% and earnings estimates by 19%.
Given such robust quarterly performance, what’s driving the selloff? Market watchers identify several company-specific headwinds rather than broader market dynamics.
Notably, major institutional shareholders have been reducing their holdings, sparking questions about valuation sustainability following the stock’s previous gains. This selling activity has created uncertainty among traders who were already monitoring the shares with caution.
Additionally, persistent concerns surrounding FDA safety notifications and product recalls associated with the da Vinci surgical platform have intensified the downturn. While these regulatory issues aren’t recent developments, they remain a persistent cloud over investor sentiment.
Wall Street Maintains Positive Outlook Despite Weakness
The recent selloff hasn’t dampened Wall Street’s enthusiasm for the stock. Bernstein SocGen Group reaffirmed its Outperform rating with an ambitious $750 price target. RBC Capital likewise maintained its Outperform stance, setting a $650 target.
Both Piper Sandler and Barclays continue to rate the shares Overweight. Piper Sandler adjusted its price objective downward to $580, while Barclays held steady at $651. Each firm highlighted strong procedure volumes and system installations as encouraging takeaways from the Q1 report.
Fifteen sell-side analysts have upgraded their earnings projections recently, and InvestingPro data indicates the stock could be trading below its Fair Value at present levels.
ISRG currently commands a market capitalization of approximately $159.4 billion. Daily trading volume typically averages around 1.9 million shares.
Technical Analysis
The technical outlook for ISRG currently registers a Hold rating. Revenue expansion over the past twelve months reached 21.43% through Q1 2026, demonstrating strong fundamental momentum despite the stock’s recent weakness.
The disparity between the stock’s 52-week peak and its current trading level illustrates the significant ground ISRG has surrendered throughout this year.
At Monday’s closing bell, ISRG finished at $423.22, representing a $26.84 decline for the session.
